The evaluation of a modified technique of Total Body Irradiation 
in respect of treatment results and toxicity by Skowrońska-Gardas, A. et al.
Total body irradiation (TBI) is a well established part of
the conditioning regimen prior to bone marrow transplan-
tation (BMT) in patients with hematological malignances.
TBI has been used since the late 1970s, originally as single
dose TBI. However this treatment schedule had been
associated with relatively high rates of acute and late
toxicity. Better understanding of the immunological
process led to an improvement of treatment results, while
the progress in radiobiology allowed to replace single dose
TBI with fractionated radiotherapy. At present numerous
different irradiation techniques and fractionation
schedules of TBI are used. There is no agreement as to
the optimal radiation method for TBI, and every center
elaborates its own solutions [1].
Bone marrow transplantation is a complicated
procedure, which may lead to early and late toxicity, to
a certain extent brought on by TBI, such as interstitial
pneumonitis, cataract and less often, thyroid, renal and
hepatic complications [2].
In our Department of Radiotherapy TBI has a long
tradition. The first patient was irradiated in 1983, using
a single dose as high as 10 Gy [3, 4]. From 1997 to 2000,
the fractionated regime was being elaborated. Over this
period we applied a TBI method involving a reduced lung
dose of 9 Gy. This method required supplementary chest
wall irradiation with an electron beam. Also, the dose
rate into mid point during the whole treatment was kept
below 0.15 Gy/min. In November 2000 a modified method
of TBI was introduced involving a higher dose to the
lungs.
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I n t r o d u c t i o n.  Total body irradiation (TBI) is a well established part of the conditioning regimen prior to bone marrow
transplantation (BMT).
Numerous different techniques are used and every center elaborates own solutions. The aim of our study to present the
method of TBI developed in our department, and to discuss the results of treatment with respect of early and late toxicity.
M a t e r i a l  a n d  m e t h o d s.  Between 11.2000 and 08.2004 23 patients were treated with fractionated TBI at the Department
od Radiotherapy of the M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsawa (MSCMCC).
Conditioning chemotherapy and BMT were performed in different hematological departments. All patients were irradiated with
a total midline dose of 12 Gy in 6 fractions over 3 consecutive days. Doses to the lung did not exceed 11 Gy.
The TBI method used in our department was evaluated over a few years. The following modifications have been introduced
to the previously applied technique: change of  photon energy from 6 MV to 15 MV; increase of lung dose from 9 Gy to 11 Gy;
the use of an individual bolus as a lung compensator in lateral fields; more frequent boost irradiation of the mediastinum and
legs with small fields; calculations of Monitor Units based on dosimetric data. Boost irradiation of the chest wall with
electrons has been abandoned. 
R e s u l t s.  Median follow up was 12 months. Up till now, 17/23 patients are alive, of these 16 with no relapse. Immediate
toxicity was low. Early complications were observed during the first 6 months after BMT in 11 patients. In the case of 4 patients
these complications were fatal. Late complications were observed in 10 patients, including chronic GVHD and hormone
disturbancy. Only one patient had developed the first symptoms of cataract. In one case Lhermitte’s syndrome was observed.
One patient died due to liver insufficiency.
C o n c l u s i o n s.  The results of treatment and the complications rates in patients treated with TBI at our department are
consistent with those published in literature. We conclud that our method of  TBI is safe and well tolerated.
Key words: total body irradiation, complications
1 Department of Radiotherapy
Maria Sk∏odowska-Curie Memorial Cancer Center 
and Institute of Oncology, Warsaw, Poland
2 Hematology and Oncology Clinic
Medical University of Warsaw, Poland
3 Department of Bone Marrow Transplantation
Military Institute of Health Services, Warsaw, Poland
The aim of our study is to present a modified
method of TBI as applied in our department, and
preliminary results, especially with respect to early and
late treatment toxicity.
Material and methods
Between 11.2000 and 08.2004 23 patients were treated
with fractionated TBI at the Department of Radiotherapy of
Maria Sk∏odowska-Curie Memorial Cancer Center.
Conditioning chemotherapy and blood marrow transplan-
tation were performed at the Hematology and Oncology
Clinic of the Medical University of Warsaw (17 patients), at
Department of Bone Marrow Transplantation of the Military
Institute of Health Services (5 patients) and, in the case of one
patient – at the Institute of Hematology and Blood Transfusion
in Warsaw.
Patient characteristics are presented in Table I.
C o n d i t i o n i n g  c h e m o t h e r a p y
Five patients received 2500 mg etoposid over one day and one
patient received a high dose of cyclophosphamid prior to TBI.
Seventeen patients were treated with etoposid 40 mg/kg body
mass and cyclophosphamid 60 mg/kg body mass administered
after TBI.
R a d i o t h e r a p y
All patients were irradiated with total midline doses of 12 Gy in
6 fractions, over 3 consecutive days. 12 Gy were prescribed to the
normalization point in the middle of an abdomen. The dose to
the lung did not exceed 11 Gy.
Radiotherapy was given with 15 MV photons. We applied
a combination of lateral fields in fractions No 1, 3, 5 and
anteroposterior with posteroanterior fields in fractions No 2
and 4. A summary of the arrangements of the TBI treatment is
presented in Table II. All irradiations without shielding blocks,
which concerned a dose of at least 8 Gy, were performed at
extended SSD of about 350 cm using horizontal beams sufficient
to encompass the whole body. A suitable filter inserted in the
beam improved dose uniformity and reduced the dose rate
during irradiation below 0.13 Gy/min in the midpoint. In lateral
fields head compensators were used. An arm with an individually
shaped bolus provided additional compensation for the lungs.
A wax bolus 6 cm thick was designed from lateral portal
film. Its shape corresponded to the visible contour of the lung.
In the anterior field in fraction 2 and in the posterior field
in fraction 4 we used partially attenuating individual lung
shielding. The lung shielding was made of layers of lead (4-6
mm thick) which reduced the lung dose by about 10%.
The patient lay supine (fraction 2) or prone (fraction 4) on
the treatment coach and was treated with 3 fields covering parts
of the body at an SSD of about 140 cm. One field to the
abdomen was treated with the gantry of 0° and other fields with
gantry angles sufficient to compensate for field divergence. In
tilted fields suitable filters were used. The dose rate for these
fields was about 1.1 Gy/min, except for the first few patients,
who were treated with a low dose rate. We had decided to
accelerate treatment with shielding to minimize movement since
it concerned only 2-4 Gy out of the entire 12 Gy. In all fields
a perspex plate 2 cm thick was placed next to the patient in
order to prevent skin sparing.
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Table II. Summary of the arrangements of the TBI treatment
Fraction Beam Gantry SSD Patient position Beam modifiers Field coverage
angle
1, 3, 5
1
90 ≈350
Supine, left side to the beam Filter nr 1, spoiler, bolus-lung Whole body
2 Supine, right side to the beam compensator, head compensator
3 -22.6 ≈150 Supine Filter nr 2, spoiler, lung shielding Head, arms and chest
4 0 ≈140 Spoiler Abdomen and thighs
2 5 22.6 ≈150 Filter nr 2, spoiler Shanks
6 90 ≈350 Straight, on the side, posterior to the beam Filter nr 2, spoiler Body without shanks
7 0 100 Prone spoiler Shanks
3 -22.6 ≈150 Prone Filter nr 2, spoiler, lung shielding Head, arms and chest
4 0 ≈140 Spoiler Abdomen and thighs
4 5 22.6 ≈150 Filter nr 2, spoiler Shanks
6 90 ≈ 350 Straight, on the side, anterior to the beam Filter nr 2, spoiler Body without shanks
7 0 100 Supine spoiler Shanks
6 Optional, dependent on the in vivo measurements of the lung dose in fractions 1-5
Table I. Patients characteristic
Gender
Male 14
Female 9
Age
<18 1
19-30 10
>30 12
Diagnosis
ALL 17
AML 3
CHL 2
NHL 1
Treatment
Primary 16
Secondary 7
Type of bone marrow transplant
Autogenic 5
Allogenic 18
Related donor 14
Unrelated donor 4
The 6th fraction was delivered with lateral or AP-PA fields,
with or without shielding, depending on the results of the lung
dose measurements during the first 5 fractions. To maintain
dose homogeneity a supplementary dose of 0.5-1.5 Gy was given
using small AP-PA fields to the mediastinum and, occasionally,
also to the pelvis and legs.
The introduction of TBI to our departamental practice
had been preceded by extensive dosimetric evaluation of the
large fields under TBI conditions. Monitor units for each field
were calculated for 1 Gy of the midpoint dose basing on SSD
measurements, patient thickness and basic dosimetric data.
Doses to the midpoint, head, lungs, legs and mediastinum were
also calculated from entrance and exit dose measurements with
MOSFET (Metal-Oxide Semiconductor Field-Effect Transistor)
detectors or TLD (thermo luminescent) discs and, additionally,
for the midpoint – with ion chambers.
Basing upon these measurements small corrections were
made in the irradiation procedure in order to achieve maximally
homogenous dose distribution within all parts of body (e.g.
thickness of boluses was modified).
The results of the in vivo dosimetry measurements using
ionization chambers remained in unison with the calculations of
the dose at midpoint. Standard deviation of dose differences
calculated for 185 measurements was equal to 2.4%, which
means, that the difference between measurements and
calculations did not exceed 5% in 95% of the cases.
The TBI method applied at our department was evaluated
over a few years. To summarize: the following modifications
have been introduced to the previously applied TBI: an increase
of photon energy from 6 MV to 15 MV; an increase of the lung
dose from 9 Gy to 11 Gy; application of individual boluses as
lung compensators in the lateral fields; more frequent boost
irradiation of the mediastinum and legs with small fields;
calculations of Monitor Units basing on dosimetric data. Boost
irradiation of the chest wall with electrons has been abandoned.
The purpose of the changes in photon energy and
application of small AP-PA fields to the mediastinum and legs
was to achieve an increase in dose homogeneity. The boluses in
the lateral fields were applied in order to decrease the dose to
the lung, while maintaining higher doses to the frontal and back
part of the chest wall. In view of the higher dose to the lung it
was possible to give up the electron boost to the chest wall.
Some smaller technical changes were also introduced to
improve dose homogeneity. For example, a suitable filter has
been designed for tilted fields. During AP or PA field irradiation
the patient lay straight on the side. The legs usually had to be
irradiated with an additional field. Previously our patients lay
with legs bent and were irradiated only with one field but usually
in those cases the dose to the legs was significantly lower in this
fraction, which could be discerned with in vivo dosimetry.
Sixteen patients had undergone’ prophylactic or thera-
peutic whole brain radiotherapy in doses of 18-30 Gy from 1 to
12 months before TBI, depending on the treatment protocols.
Sixteen patients received TBI as primary treatment, and
7 were treated due to relapse.
E v a l u a t i o n  o f  s i d e  e f f e c t s
We evaluated all side effects possibly connected with TBI.
Immediate toxicity was evaluated prior to each fraction (twice
a day). We considered all complications observed during the
first 6 months after the graft as early complications.
All complications diagnosed more than 6 months after
irradiation, especially pulmonary complications, were recognized
as late toxicity. Clinical pulmonary complications and X-ray
findings were graded according to the scale presented by Lohr
[5] (Table III). Renal dysfunction was assessed on the basis of the
serum creatinine and urea levels 6 months after the completion
of radiotherapy. Ocular complications, especially cataract,
(proven ophtalmologically) were assessed during follow-up more
than 6 months after treatment. Other complications, such as as
hormonal insufficiency, xerostomia and alopecia were also
evaluated.
Table III. Late pulmonary complications (Lohr scale)
Grade Details
1 No lung complications at all, no X-ray findings
2 Lung complications / X-ray findings – minor clinical
3 Severe pulmonary complications
4 Fatal lung complications
The survival data were calculated according to the Kaplan-
Maier method.
Due to the limited number of patients we refrained from
performing any further statistical analyses.
Results
The follow-up was closed on March 30th, 2005.
Median follow-up was 12 months (range: 5 days –
52 months). At present 17 patients are alive, of these
16 with out relapse. Six patients have died, 5 due to
complications of treatment, and one with recurrent
disease and complications after the second graft. The
probability of overall survival is presented in Figure 1.
Patients who had received TBI as primary treatment
have achieved significantly better event-free survival than
patients treated due to relapse (p=0.046).
I m m e d i a t e  t o x i c i t y
Main symptoms observed during irradiation included
mild nausea and emesis in 12 patients. Mild xerostomia
(mouth dryness, slightly thickened salivary, slightly altered
taste) was observed in 11 patients. Two patients reported
mild gastro-intestinal effects, such as loss of appetite and
mild diarrhea. Generally TBI tolerance was good.
E a r l y  c o m p l i c a t i o n s – were observed during the
first 6 months after transplantation in 11 patients and
included: interstitial pneumonitis in 2 cases, oesophagitis
in 1 case, trombocytopenia in 2 cases, hemorrhagic cystitis
in 2 cases and acute GVHD in 6 cases. In 4 cases these
complications were fatal. One patient died 5 days after
137
1
0.8
0.6
0.4
0.2
0
0 3 6 9 12 15 18 21 24 27 30 33 36
Follow-up (months)
p
ro
b
ab
o
lit
y
Figure 1. Overall survival after TBI
treatment due to immediate complications related to the
transplant. Two patients died after one month – one
because of multiorgan insufficiency and one due to
cytomegalovirus infection. The fourth patient developed
acute GVHD, and died among symptoms of interstitial
alveolar pneumonitis and fungoidal infection 6 months
after the transplant.
L a t e  c o m p l i c a t i o n s
Only one patient died due to late complications, after
a period of 12 months due to Hepatitis B Virus infection
and liver insufficiency.
Among the 16 patients, who are alive without relapse
after six months, late complications were observed in 10
cases. Thirteen patients showed no radiographic changes
on chest X-ray, in 3 cases we have not obtained the chest
X-rays, but they do not report nor show any clinical
pulmonary symptoms. They are all pronounced as grade I
acc. to the Lohr scale. Only one patient reports first
symptoms of cataract, proven ophtalmologically, 36
months after treatment. Three patients had elevated
serum creatinine and urea levels, but they had all been
administered cyclosporine. All women alive without
relapse (i.e. 5) have ovary function disturbances,
associated with preliminary menopause symptoms.
We have observed persistent mouth dryness in 3
cases and mild allopecia in 2 cases. One patient reported
“shocks” along the spine, recognised as Lhermitte’s
syndrome. These symptoms were mild and transient.
Six patients after allogenic transplant, are alive with
symptoms of chronic GVHD.
Discussion
Different irradiation and fractionation schemes were used
for total body irradiation, depending on local facilities
and study protocols. Generally, the symptoms of toxicity
depend on the total dose, fractionation doses and patient
related factors, as well as on transplantation modalities [2,
6, 7].
Overall and disease-free survival rates of 3-5 years in
larger patient populations have been reported by some
authors to reach 50-70% [8, 9, 10]. The results depended
on diagnosis, type of treatment (primary vs. for relapse),
patient age etc. Our results – 74% and 70%, respectively,
resemble those reported in literature.
Immediate toxicity during fractionated TBI was low
in our patient group. The main symptoms consisted of
mild nausea and emesis and xerostomia, observed in
about 50% of patients. The incidence of diarrhea was as
low as 8%. These observations are similar to those
presented by other authors [11].
Early and late toxicity is related to the cytoreductive
regimen (conditioning chemotherapy and radiotherapy)
and to the transplantation itself. Acute GVHD (graft-
versus-host disease) is a syndrome consisting of
dermatitis, hepatitis and enteritis, which appears within
100 days of allogenic transplant. Interstitial pneumonitis
is related to the severity of acute GVHD. Chronic
GVHD, which develops more than 100 days after
allogenic graft, tends to result in widespread organ
involvement (skin, liver, lungs, eyes and GI tract) and
behaves like an autoimmune process [1].
In our study 4 patients died due to early compli-
cations, related directly to the transplantation itself.
Total body irradiation can be responsible for some
late complications. Of these one of the most important is
interstitial pneumonitis (IP). One of the causes of IP is
GVHD the case of patients treated with allogenic bone
marrow transplant. The incidence of IP in these patients
could be as high as 25% and fatal for many of them
(20%) [12].
In patients treated with autogenic BMT the overall
5-year IP incidence is less than 20%, depending on the
dose-rate of TBI and the age of the patients [5, 9]. In
order to prevent lung complications, many centers apply
individual lung shielding and the lung dose was limited to
9 Gy [2, 9, 10, 13-15]. However, some authors have
reported a low incidence of lung complications after
higher radiation doses, up to 12-13 Gy [5, 7, 16].
When the lung dose is reduced to 9 Gy, the chest
wall has to be treated with supplementary electron fields.
In order to encompass ribs, electron energy has to be
relatively high. Therefore the electrons penetrate deep in
the lung and the effect of lung sparing is lost. Electron
chest wall irradiation is especially difficult in women
because of the presence of breasts.
In our material, despite the higher lung dose, within
the range of 10-11 Gy, only 2 (8%) patients developed
symptoms of IP within a period of 6 months after the
transplant. In the remaining patients we did not observe
any lung complications, which was confirmed by chest X-
ray.
Because the lung complication rate was low, we
conclude that the treatment regime applied in our
department is safe.
TBI also can be responsible for some other late
organ complications, such as cataract or liver insufficiency.
Post-TBI cataract is observed in 10-30% of patients, 2
a years and more after treatment. The estimated
cumulative risk for cataract development at 15 years is
reported to exceed 50% [17]. Single fraction high dose
TBI may be associated with a higher risk of cataract than
fractionated schedules [2, 17, 18]. In our data, the first
symptoms of cataract were diagnosed in one patient only,
but longer follow-up is necessary.
The risk of renal toxicity after TBI is low. Borg at al.
presents only one case of radiation nephritis in a study
encompassing 59 patients – 24 months after completion of
TBI [19]. In our study, 3 patients had elevated serum
creatinine and urea levels, probably related to the
cyclosporine, which they had been administered.
Gonadal failure is a common long-term consequence
both of chemotherapy and radiotherapy, and the ovaries
are more vulnerable to irradiation and chemotherapy
than the testes [6]. In our patient group all women
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suffered disturbances in ovarian function, associated
with preliminary menopause syndrome.
Radiation myelitis has been reported as an unexpec-
ted complication following TBI, allogenic stem cell
transplantation and mediastinal involved field irradiation
[20]. We have observed symptoms of Lhermitte’s syn-
drome in one patient, but they were mild and transient. 
This particular patient had also undergone pro-
phylactic whole brain irradiation. 
In conclusion, the results of treatment and
complication rates observed in the patient group treated
with TBI at our department resemble those reported by
other authors. We conclud that our TBI method is safe
and well tolerated, but a longer follow-up period is
necessary to present more complex results.
Anna Skowroƒska-Gardas MD, PhD
Radiotherapy Department
Maria Sk∏odowska-Curie Memorial Cancer Centre
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